E13.620: Other specified diabetes mellitus with diabetic dermatitis
E13.620 is a billable, specific ICD-10-CM code for other specified diabetes mellitus with diabetic dermatitis. It is valid for submission on a claim.
Check E13.620 with the rest of the claim: free scrubberInclusion terms
Alternative wordings a physician may use in the chart for this same code.
- Other specified diabetes mellitus with diabetic necrobiosis lipoidica
Excludes1 inherited from the categories above E13.620
A category’s note binds every code beneath it.
Written on E13: Other specified diabetes mellitus
- diabetes (mellitus) due to autoimmune process (E10.-)
- diabetes (mellitus) due to immune mediated pancreatic islet beta-cell destruction (E10.-)
- diabetes mellitus due to underlying condition (E08.-)
- drug or chemical induced diabetes mellitus (E09.-)
- gestational diabetes (O24.4-)
- neonatal diabetes mellitus (P70.2)
- type 1 diabetes mellitus (E10.-)
Other codes that can never be billed with E13.620
Their own Excludes1 notes name this code, so the conflict is not listed above.
Risk adjustment
E13.620 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 37 Diabetes with Chronic Complications0.166 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score. Look up the whole chart to see which of its HCCs the hierarchy would zero.
Medicare coverage
E13.620 is named in 25 Medicare coverage policies: 25 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.
- A52464Glucose Monitor - Policy Article
- A52501Therapeutic Shoes for Persons with Diabetes - Policy Article
- A52507External Infusion Pumps - Policy Article
- A52996Billing and Coding: Routine Foot Care
Alphabetic index entries that lead here
- Diabetes, diabetic›specified type NEC›with›dermatitis
- Diabetes, diabetic›specified type NEC›with›necrobiosis lipoidica
Code history
Unchanged in every release from FY2024 to FY2027.